Medical Nutrition Therapy & Metformin in Early Gestational Glucose Intolerance to Prevent
Post-Partum Diabetes Risk in a Hospital Prospective Study
Shweta Verma*1, Renu Gupta2, Neena Gupta3, Divya Dwivedi4 , Palak Taneja5
Submitted: 10 Dec 2025; Accepted: 25 Dec 2025; Published: 10 Jan 2026
Abstract
Objectives
This study examines how Medical Nutrition Therapy (MNT) and Metformin help manage early gestational glucose intolerance
during the 8th-10th weeks of pregnancy, particularly when postprandial blood glucose (PPBG) is >110 mg/dL. The goal is to
find out if these treatments can prevent gestational diabetes mellitus (GDM) and lower the risk of diabetes after pregnancy.
Material and Methods
A prospective cohort study was conducted at the GSVM Medical Hospital in Kanpur, involving approximately 231 pregnant women
at 8 to 10 weeks of gestation with pre-prandial blood glucose (PPBG) levels of at least 110 mg/dL. Participants were randomly
assigned to either the MNT-Metformin group, receiving dosages ranging from 500 to 2500 mg, or the MNT-only group.
Results
At 2 to 3 days postpartum and at 6 weeks, the mean PPBG for the Metformin plus MNT group was 106.9 ± 5.24 mg/dL and
107.51 ± 10.67 mg/dL, respectively (P = 0.57). The mean HBA1c values were 4.84 ± 0.20 and 4.99 ± 0.37, respectively, with a P-value
< 0.05.
Conclusion
Early detection and management of early gestational glucose intolerance (EGGI) with medical nutrition therapy (MNT) and
Metformin can reduce the risk of progression to diabetes during postpartum screening.
Keywords: EGGI Early gestational glucose intolerance, Gestational diabetes mellitus (GDM), PPBG: Postprandial blood
glucose, MNT Medical Nutrition Therapy, OGCT Oral Glucose Challenge Test, DIPSI diabetes in Pregnancy Study Group India.
